Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegargiminase + venetoclax + azacitidine
- Development stage
- Unknown
- Lead developer
- Polaris Group
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral, Subcutaneous, Intravenous
01
Overview
Pegargiminase + venetoclax + azacitidine is an investigational triplet combination therapy being developed by Polaris Group in collaboration with MD Anderson Cancer Center. The regimen combines pegargiminase (ADI-PEG 20), a PEGylated arginine-degrading enzyme, with the standard-of-care doublet of venetoclax (a BCL-2 inhibitor) and azacitidine (a hypomethylating agent). Pegargiminase works by depleting extracellular arginine, targeting tumors that are deficient in argininosuccinate synthetase (ASS1), such as acute myeloid leukemia (AML). This metabolic targeting is intended to sensitize AML cells to the pro-apoptotic effects of venetoclax and the epigenetic modifications induced by azacitidine. The combination is currently in Phase 1 clinical trials for newly diagnosed adverse-risk and relapsed/refractory AML.
- Brand names
- Hepacid + venetoclax + azacitidine
- Other names
- ADI-PEG 20 + venetoclax + azacitidine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)BCL-2 (BCL-2 family)L-arginine
Beyond the preview
Go deeper on pegargiminase + venetoclax + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegargiminase + venetoclax + azacitidine.